Open AccessDifficult-to-treat rheumatoid arthritis. What is it?
Author(s) -
А. В. Гордеев,
Ю. А. Олюнин,
Е. А. Галушко,
Е. Г. Зоткин,
А. М. Лила
Publication year - 2021
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2021-5-7-11
Subject(s) - rheumatoid arthritis , medicine , antirheumatic drugs , disease , intensive care medicine , quality of life (healthcare) , antirheumatic agents , clinical practice , physical therapy , disease management , nursing , parkinson's disease
The widespread introduction into clinical practice of modern approaches to the treatment of rheumatoid arthritis (RA), the rational use of traditional and targeted antirheumatic drugs can effectively suppress inflammatory activity, restrain the progression of the disease and improve the quality of life of patients. At the same time, in some patients, even after the repeated change of targeted drugs, it is not possible to achieve the target level of RA activity. Serious difficulties arising in the management of such patients raised the question of identifying a special variant of the disease – difficult-to-treat (D2T) RA. The presence of various variants of D2T RA and the need to use a personalized approach to therapy justify the creation of special recommendations for the management of this category of patients. The first step in preparing these recommendations was the definition of D2T RA recently presented by the EULAR working group. It includes three criteria: 1) insufficient effectiveness of the therapy; 2) the presence of an active symptomatic disease; 3) clinical perception.